Table 2

Disease characteristics at inclusion of the 40 patients with an increase in damage and of those 97 with a stable damage score at follow up and in brackets damage scores at follow up

SDI/BILAG; SF-20+; drug scores Patients with increase in damage (median; range) Patients with stable damage (median; range)
Total damage1; 0–7 (3; 1–7)0; 0–5 (0; 0–5)
Neuropsychiatric damage0; 0–2 (0; 0–3)0; 0–2 (0; 0–2)
Renal damage0; 0–3 (0; 0–3)0; 0–3 (0; 0–3)
Musculoskeletal damage0; 0–2 (0; 0–3)0; 0–3 (0; 0–3)
BILAG total score4;1–174;0–17
General BILAG1; 0–31; 0–9
Mucocutaneous BILAG0; 0–30; 0–9
Neurological BILAG0; 0–30; 0–9
Musculoskeletal BILAG1;0–91;0–9
Cardiovascular/respiratory BILAG0; 0–30; 0–3
Vasculitis BILAG0; 0–30; 0–3
Renal BILAG0; 0–30; 0–3
Haematological BILAG0; 0–90; 0–3
SF-20+: physical functioning* 50; 0–10067; 0–100
SF-20+: role functioning* 50; 0–10050; 0–100
SF-20+: social functioning* 60; 0–10080; 0–100
SF-20+: mental health* 68; 16–10068; 20–100
SF-20+: health perception* 30; 0–8747; 0–100
SF-20+: pain75; 0–10050; 0–100
SF-20+: fatigue70; 0–10070; 0–100
Drug score1; 0–31; 0–3

  • Organ damage item only given if mean score at inclusion ⩾0.1 (and at three years >0.12). Lower scores always mean better health except for the SF-20+ scores marked with *.